Keyword Search
 

Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer

Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality

Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer

Ocular Therapeutix™ to Report Second Quarter 2017 Financial Results

Ocular Therapeutix™ Receives Complete Response Letter from FDA for DEXTENZA™ NDA

Ocular Therapeutix™ Submits Amendment to Potentially Extend Review for DEXTENZA™ New Drug Application (NDA)

Ocular Therapeutix™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)